<DOC>
	<DOCNO>NCT02766049</DOCNO>
	<brief_summary>The aim study assess tolerability safety three different formulation anti-HIV immunotherapy base autologous dendritic cell ( DCs ) pulse HIV chemically inactivate Aldrithiol™-2 ( AT-2 ) . Patients chronically infected HIV , naïve antiretroviral drug . A possible immunological virological favorable impact also assess .</brief_summary>
	<brief_title>Study Anti-HIV Cellular Therapy Based Dendritic Cells Pulsed With Chemically Inactivated Virus</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<criteria>patient HIV infection ; absence antiretroviral therapy , antineoplastic therapy use corticosteroid least six month prior study entry ; plasma viral load ≥ 1,000 copy / mL , stable ( ie variation &gt; 0.5 log ) six month start study ; blood CD4+ T cell ≥ 350 /mL , stable ( ie variation &gt; 25 % ) six month start study . individual without proper venous access blood apheresis collection procedure . use drug , alcohol , psychiatric disorder condition interfere ability patient follow requirement study ; history diagnosis HIV infection &lt; 01 year ; pregnancy breastfeeding ; use antiviral therapy , anticancer therapy corticosteroids six month prior study start ; presence chronic disease , infection hepatitis B ( HBV ) C ( HCV ) , human Tlymphotropic virus ( HTLV ) I / II condition promotes immune system dysfunction , exception HIV infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>HIV</keyword>
	<keyword>immunotherapy</keyword>
	<keyword>clinical trial</keyword>
	<keyword>dendritic cell</keyword>
</DOC>